Form 4: AbCellera Director Stephen Quake Receives Option Grant

Director Stephen Quake was granted options to purchase 111,701 common shares of AbCellera Biologics Inc. on June 11, 2026.

Summary

• Director Stephen Quake received a grant of 111,701 share options.
• The options have an exercise price of $5.27 per share.
• The options are set to vest at the 2027 Annual General Meeting.
• The expiration date for these options is June 11, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential future dilution of existing shareholders upon the exercise of these options.

Risks

• Vesting is contingent upon the reporting person's continuous service to the issuer.

Future Outlook

The options vest at the 2027 Annual General Meeting, indicating a long-term retention incentive for the director.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard practice in the biotechnology sector to ensure alignment between leadership and long-term corporate performance.

Comparison to Industry Standards

• The grant of stock options to non-executive directors is consistent with standard corporate governance practices for publicly traded biotech firms.
• The vesting schedule tied to an annual meeting is a common mechanism for director compensation.

Stakeholder Impact

• Minor potential dilution for existing shareholders if options are exercised in the future.

Next Steps

• Vesting of options at the 2027 Annual General Meeting.

Key Dates

Keywords

AbCellera, ABCL, Director, Insider Trading, Stock Options, Biotech